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Abstract
Background: One of the recognized treatment options for patients with polycystic ovarian syndrome (PCOS) is in vitro 
fertilization (IVF) or intracytoplasmic sperm injection (ICSI). Fears are however sometimes raised concerning the likely 
outcome of treatment in such patients compared with their counterparts with tubal factor infertility.
Objective: To compare the IVF/ICSI performance in women with PCOS and those with tubal factor infertility.
Materials and Methods: A retrospective analysis. Case notes of 30 patients, 35 years and below, with PCOS and 
who underwent 33 IVF/ICSI cycles and those of 42 age-controlled patients with tubal factor infertility and who had 
43 cycles between December 2004 and April 2008 were retrieved. Data including duration of down-regulation, dose of 
human Menopausal Gonadotropin (hMG), number of cancelled treatments, endometrial thickness, number of oocytes 
retrieved and fertilization rate, in addition to the number of embryos transferred with resultant pregnancy outcome 
were compared between the two groups. The main outcome measures were response to gonadotropin stimulation, 
fertilization rate and clinical pregnancy rate.
Results: There was no significant difference between the PCOS group and the tubal factor infertility group in the hMG 
dose (2.7 vs. 3.4 vials, respectively), endometrial thickness (10.5 vs. 10.1 mm, respectively) and embryos transferred 
(3.1 vs. 2.9, respectively). The fertilization rate was significantly higher in the tubal factor infertility group, which was 
81.48% as against 63.24% for the PCOS group (P < 0.0001). While more cases of ovarian hyperstimulation syndrome 
(OHSS) occurred in the PCOS group (P = 0.049), overall clinical pregnancy rate per embryo transfer was similar (45.45% 
vs. 42.85%; P = 1), with similar miscarriage rates.
Conclusion: IVF/ICSI performance in patients with PCOS is probably similar to their counterparts with tubal factor 
infertility with, however, a reduced fertilization rate and higher incidence of OHSS.
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Introduction
Polycystic ovarian syndrome (PCOS) is a common endocrine 
condition with an estimated prevalence of approximately 
4–8%, but as high as 25% in some populations.[1] It 
is reported that over 70% of women suffering from 
normogonadotrophic anovulation present with ultrasound 
or endocrine features associated with PCOS.[2]
Ovulation induction with pharmacological agents constitutes 
the first-line treatment of choice in these women.[3] First-line 
agent of choice is the antiestrogen clomiphene citrate, while 
exogenous gonadotropins are commonly used as second-
line intervention.[3,4] Unfortunately, multiple pregnancy 
rates with the above, especially with gonadotropins, are 
considerably high.[5] While some patients will benefit from 
any of these treatments, a considerable number will require 
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other forms of assisted conception such as in vitro fertilization 
(IVF) or intracytoplasmic sperm injection (ICSI).[6] With 
IVF/ICSI, the number of embryos transferred can be 
determined and it can therefore be possible to reduce the 
multiple pregnancy rates.
Several protocols exist for controlled ovarian stimulation. 
These include the ultra-short, short, and the long 
protocols.[7] The long protocol has the effect of suppressing 
endogenous gonadotropins. This is particularly relevant 
in patients with PCOS as they commonly have an 
elevated luteinizing hormone (LH) levels with subsequent 
elevation of androgens. The reversible hypogonadotropic 
hypogonadism so produced permits unimpeded control 
over follicular development, thereby allowing the oocyte 
containing follicles to develop in the sensitive polycystic 
ovary, free from the adverse environment of high tonic LH 
levels. These oocytes appear to fertilize better than those 
obtained in cycles without pituitary desensitization.[8]
Concerns have however been raised regarding the risk of 
ovarian hyperstimulation syndrome (OHSS), fertilization as 
well as pregnancy rates in this group of patients.
The aim of this study, is to compare the IVF/ICSI 
performance in women with PCOS with their age-matched 
counterparts with tubal factor infertility.
Materials and Methods
A retrospective analysis was carried out at the Port 
Harcourt Fertility Centre, Rivers State, Nigeria. Case 
notes of 30 patients, 35 years and below, with PCOS and 
who underwent 33 IVF/ICSI cycles and those of 42 age-
controlled patients with tubal factor infertility diagnosed 
on hysterosalpingogram, with normal ovaries, and who 
had 43 cycles between December 2004 and April 2008 
were retrieved. Those who had male factor infertility or 
combined PCOS and tubal factor infertility were excluded 
from the study. All patients with PCOS were placed on 
metformin tablets 500 mg b.d. before the commencement 
of pituitary down-regulation. Data including duration of 
down-regulation, dose of human Menopausal Gonadotropin 
(hMG), number of cancelled treatments, endometrial 
thickness, number of oocytes retrieved and fertilization 
rate, in addition to the number of embryos transferred 
with resultant pregnancy outcome were compared between 
the two groups. Data were analyzed with SPSS statistical 
package. Cycle parameters were compared using the 
Student’s t-test and Fisher’s exact test. A P-value of <0.05 
was considered statistically significant at 95% confidence 
interval.
For the purpose of this study, PCOS was defined as 
anovulation/oligoanovulation and clinical and/or 
biochemical evidence of hyperandrogenism and polycystic 
appearance on ultrasound scan.[9] All three criteria were 
present in the 30 patients.
Main outcome measures were response to gonadotropin 
stimulation, fertilization rate, and clinical pregnancy rate.
Results
As shown in Table 1, there was no significant difference in 
age, hMG dose (2.7 vs. 3.4 vials), and endometrial thickness 
(10.5 vs. 10.1 mm) between the PCOS group and the 
tubal factor infertility group (P = 0.152, 0.137, and 0.414, 
respectively).
Table 2 compares the stimulation, fertilization, and clinical 
outcome between the two groups. Although a greater 
number of oocytes were retrieved from the PCOS group 
(12.7 vs. 9), the fertilization rate was significantly higher 
in the tubal factor infertility group, which was 81.48% as 
against 63.24% for the PCOS group (P < 0.0001).
While more cases of OHSS occurred in the PCOS group 
(P = 0.049), overall clinical pregnancy rate per embryo 
transfer was similar (45.45% vs. 42.85%; P = 1) with 
similar miscarriage rates (12.12% vs. 11.63%). Take-home 
baby rate was 36.41% and 30.27% for the PCOS and tubal 
factor infertility groups, respectively.
Discussion
The aim of every IVF program is to achieve multifollicular 
development resulting in the collection of several 
appropriately matured eggs without causing OHSS. This is 
especially so in women with PCOS as they usually exhibit 
Table 1: Comparison of age, HMG dose, and 









Age (years) 30.24 ± 3.99 30.65 ± 2.68 0.152
hMG dose (vials) 2.7 ± 0.88 3.4 ± 1.14 0.137
Endometrial
thickness (mm) 10.5 ± 2.45 10.1 ± 2.15 0.414
Table 2: Stimulation, fertilization, and clinical outcome
Cycle parameters PCOS (n = 33) Tubal factor 
(n = 43)
P value
Oocytes retrieved 12.7 ± 7.69 9 ± 6.27 0.021∗
Fertilization rate (%) 265/419 (63.24) 242/297 (81.48) <0.0001∗
Embryos transferred 3.1 ± 1 2.9 ± 0.89 0.169
OHSS rate (%) 6 (18.18) 3 (6.98) 0.049∗
Clinical pregnancy (%) 15 (45.45) 18 (42.85) 1
Miscarriage rate (%) 4 (12.12) 5 (11.63) 0.926
∗Significant
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greater sensitivity than women with normal ovaries to 
exogenous stimulation.[10] In our study, although fewer 
ampoules of hMG were used for stimulation of the patients 
with PCOS compared to those with normal ovarian 
function, the difference was not statistically significant 
(P = 0.137). Despite this, significantly more patients with 
PCOS had OHSS (P = 0.049). This again might be a 
reflection of the extreme sensitivity of patients with PCOS 
to gonadotropins as already alluded to. In a study by Urman 
et al.,[11] patients with PCOS used a significantly lower dose 
of hMG compared to those with normal ovaries. In another 
study, despite using the same dose of hMG, significantly 
more cycles were cancelled in the PCOS group because of 
imminent OHSS (6% vs. 1%).[12]
While gonadotropin-releasing hormone (GnRH) antagonist 
protocol is associated with lower incidence of OHSS,[13] we 
still prefer the long protocol of pituitary desensitization with 
GnRH agonist as it allows for better flexibility necessary 
for batching our patients.[14] With the long protocol, we 
are able to commence controlled ovarian stimulation in all 
batched patients at the same time following variable periods 
of pituitary down-regulation.
Patients with PCOS have higher estradiol levels compared 
with their counterparts with normal ovarian function.[15] 
Estradiol levels give an indication of the risk of OHSS, and 
the higher the estradiol level, the greater is the risk of OHSS. 
Unfortunately, we rely solely on endometrial thickness 
on transvaginal ultrasound scan for cycle monitoring 
during ovarian stimulation and so cannot comment on 
the estradiol levels in our patients. This is not out of 
place as there are reports that estradiol levels are a poor 
predictor of treatment success and, when done routinely, 
do not reduce the incidence of OHSS.[16] Estradiol levels 
are probably only necessary in patients at risk of OHSS on 
ultrasound scanning. [16] Endometrial thickness also has a 
good correlation with estradiol levels, while the number of 
developing follicles can predict the risk of OHSS.[17,18] All our 
patients with suspected risk of OHSS based on the number 
of developing follicles, especially if more than 20, were 
“coasted” for 1–2 days. There are reports that this reduces 
the serum estradiol levels and subsequently reduces the risk 
of OHSS.[19] Prolonged coasting for more than 3 days might, 
however, be associated with poor clinical outcome. [20,21] 
Despite this measure, we still recorded a higher OHSS rate 
in the PCOS group, though none was severe. There was 
no statistically significant difference in the endometrial 
thickness at the point of human chorionic gonadotropin 
(hCG) administration between the two groups of patients 
(P = 0.414).
Oocyte recovery was significantly more in the PCOS 
group, as observed in other studies.[22-24] It is our practice 
to carry out ICSI in patients with previous history of 
fertilization failure from IVF or whenever we use frozen or 
overnight semen sample from those previously identified 
to be at risk of psychogenic anejaculation. Oocyte quality 
was not compared between the two groups in our study. 
Fertilization rate was, however, significantly more in the 
tubal factor infertility group (P < 0.0001). We cannot 
conclude if this is a reflection of poorer egg quality or as 
a result of significantly more immature eggs in the PCOS 
patients. While significantly more oocytes were recovered 
by Plachot and coworkers[23] (12.1 vs. 9.6), a significantly 
greater percentage of the oocytes were immature (13.8 vs. 
5.8%). Another recent study did not observe any difference 
in the maturity of the oocytes or oocyte dysmorphism 
between patients with PCOS and those with normal 
ovarian function.[15] The role of premature administration 
of hCG because of the fear of OHSS, as a possible reason 
for the occurrence of significant number of immature 
oocytes in patients with PCOS, needs to be investigated. 
Importantly though, reduction of the adverse hormonal 
milieu of the developing follicle in PCOS would ultimately 
lead to better quality oocytes. While there are reports that 
pituitary desensitization for up to 14 days might be enough 
to achieve this, some investigators recommend a longer 
period of desensitization for up to 30 days, especially for 
patients with PCOS.[25]
The cumulative clinical pregnancy rate was the same for 
the two groups of patients (P = 1) as was observed in other 
studies.[26] There was no significant difference in miscarriage 
rates between the two groups contrary to some reports.[15,27] 
This observation might be as a result of the application of 
our protocol which involves placing all patients with PCOS 
on metformin prior to commencing treatment. Metformin 
has been shown by various studies to reduce the miscarriage 
rates in patients with PCOS undergoing IVF treatment.[28,29] 
While reports show that PCOS patients demonstrate a 
significantly increased chance of cycle cancellation (12.8% 
vs. 4.1%),[26] no cycle was cancelled in our study. While our 
practice of coasting such patients might have played a role, 
our sample size was, however, small.
Our study suggests that IVF/ICSI performance in patients 
with PCOS might be as good as their counterparts with tubal 
factor infertility. The small sample size, however, limits a 
more definitive conclusion. Further randomized controlled 
studies are required.
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